Bausch Health Companies I... (BHC)

NYSE: BHC · Real-Time Price · USD

5.29

-0.01 (-0.19%)

At close: May 01, 2025, 3:59 PM

5.30

0.19%

After-hours: May 01, 2025, 04:05 PM EDT

-0.19% (1D)

Bid	5.02
Market Cap	1.95B
Revenue (ttm)	9.6B
Net Income (ttm)	-42.62M
EPS (ttm)	-0.13
PE Ratio (ttm)	-40.69
Forward PE	1.13
Analyst	Hold

Ask	5.47
Volume	2,734,054
Avg. Volume (20D)	2,726,604.4
Open	5.20
Previous Close	5.30
Day's Range	5.00 - 5.34
52-Week Range	3.96 - 9.85
Beta	0.43

About BHC

Bausch Health Companies Inc., together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment offers products with a focus on...

Sector Healthcare

IPO Date Mar 29, 1994

Employees 20,700

Stock Exchange NYSE

Ticker Symbol BHC

Website https://www.bauschhealth.com

Full Company Profile

Analyst Forecast

According to 5 analyst ratings, the average rating for BHC stock is "Hold." The 12-month stock price forecast is $8, which is an increase of 51.23% from the latest price.

Stock Forecasts

Earnings Surprise

New

Bausch Health Companies has released their quartely earnings on Apr 30, 2025:

Revenue of $2.26B misses estimates by $31M, with 4.92% YoY growth.

EPS of 0.61 misses estimates by -0.24, with 3.39% YoY growth.

Why Price Moved

1 week ago

+9.96%

Bausch Health shares are trading higher after anno... Unlock content with Pro Subscription

2 months ago

+10.29%

Bausch Health shares are trading higher after the company reported better-than-expected Q4 sales.

News

Just now · zacks.com

Bausch Health Q1 Earnings and Revenues Miss Estimates, Stock Down

BHCs first-quarter 2025 adjusted earnings and revenues miss estimates. Salix performs lower than expected.

22 hours ago · zacks.com

Bausch (BHC) Reports Q1 Earnings: What Key Metrics Have to Say

The headline numbers for Bausch (BHC) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates ...

23 hours ago · zacks.com

Bausch Health (BHC) Q1 Earnings and Revenues Lag Estimates

Bausch Health (BHC) came out with quarterly earnings of $0.59 per share, missing the Zacks Consensus Estimate of $0.83 per share. This compares to earnings of $0.59 per share a year ago.

1 day ago · seekingalpha.com

Bausch Health Companies Inc. (BHC) Q1 2025 Earnings Call Transcript

Bausch Health Companies Inc. (NYSE:BHC ) Q1 2025 Earnings Conference Call April 30, 2025 5:00 PM ET Company Participants Garen Sarafian - IR Thomas Appio - CEO Jean-Jacques Charhon - EVP & CFO Confere...

1 day ago · accessnewswire.com

Bausch Health Announces First Quarter 2025 Results

First Quarter Consolidated Revenues of $2.26 billion, up 5% on a Reported basis and 6% on an Organic (non-GAAP) 1 basis over the prior year period GAAP Net Loss Attributable to Bausch Health Companies...

2 days ago · accessnewswire.com

Bausch Health Announces Health Canada Clearance of Solta Medical's Thermage(R) FLX System

A Long-Awaited Advancement in Non-Invasive Radiofrequency Skin Tightening Is Now Approved for the Canadian Market LAVAL, QC / ACCESS Newswire / April 29, 2025 / Bausch Health Companies Inc. (NYSE:BHC)...

1 week ago · zacks.com

Will Bausch (BHC) Beat Estimates Again in Its Next Earnings Report?

Bausch (BHC) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

1 week ago · zacks.com

Bausch Health (BHC) Reports Next Week: Wall Street Expects Earnings Growth

Bausch (BHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 week ago · wsj.com

Bausch Health Learns Icahn Has 34% Economic Interest in Shares

Activist investor Carl Icahn has tightened his hold on pharmaceutical company Bausch Health.

1 week ago · reuters.com

Bausch Health says Carl Icahn has exposure to about 34% of company's shares

Billionaire Carl Icahn has a total economic exposure of about 34% to Bausch Health's common shares, the healthcare firm said in a filing on Tuesday.

Load More News